| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Background and Design: S100A12 is an endogenous receptor ligand for advanced glycation end products. Cardiovascular disease remains a major cause of morbidity and mortality in patients with chronic kidney disease. In this study, we report two-year prospective study on 847 hemodialysis patients and assess the relationship between plasma S100A12 level and cardiovascular disease. We investigated the onset or death of cardiovascular disease as an endpoint.
Results: During the follow-up, 35 cardiovascular deaths were occurred. S100A12 level, measured at baseline, was significantly elevated in dead patients compared with survived patients. Cumulative incidence of cardiovascular death by Kaplan-Meier estimation was significantly higher in the higher half of plasma S100A12 than in the lower half.
Conclusions: Plasma S100A12 is elevated in the cardiovascular dead, and high circulating S100A12 is a predictor for cardiovascular mortality in ESRD patients.
|
